Regulatory framework for access to safe, effective quality medicines

Antiviral Therapy

Volumn 19, Issue , 2014, Pages 69-77

  Rägo, Lembit ^a   Sillo, Hiiti ^b   'T Hoen, Ellen ^c   Zweygarth, Monika ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Tanzania Food and Drugs Authority   (Tanzania)

^c Medicines Law and Policy ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ARTEMISININ; COUNTERFEIT DRUG; GENERIC DRUG;

DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG THERAPY; ECONOMICS; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH PROMOTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL COOPERATION; MALARIA; NATIONAL HEALTH ORGANIZATION; PATENT; PHARMACEUTICAL CARE; POLICY; PRACTICE GUIDELINE; PRODUCT SAFETY; PUBLIC HEALTH; PUBLIC-PRIVATE PARTNERSHIP; QUALITY CONTROL; REVIEW; STANDARDIZATION; SUPPLY AND DISTRIBUTION; THERAPEUTIC EQUIVALENCE; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COUNTERFEIT DRUGS; DRUG APPROVAL; DRUG THERAPY; DRUGS, GENERIC; ECONOMICS; GUIDELINES AS TOPIC; HIV INFECTIONS; HUMANS; INTERNATIONAL COOPERATION; ORGANIZATIONAL POLICY; QUALITY CONTROL; SUPPLY AND DISTRIBUTION; THERAPEUTIC EQUIVALENCY; WORLD HEALTH ORGANIZATION;

EID: 84964199228     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2902     Document Type: Review

References (24)

1. World Health Organization. WHO model lists of essential medicines. (Updated October 2013. Accessed 13 May 2014.) Available from http://www.who.int/medicines/publications/essentialmedicines/en/index.htm
2. World Health Organization. Good governance for medicines (GGM) overview. (Updated May 2013. Accessed 23 June 2014.) Available from http://www.who.int/medicines/areas/policy/goodgovernance/en
3. Ratanawijitrasin S, Wondemagegnehu E. Effective drug regulation: a multicountry study. WHO. (Updated 2002. Accessed 11 February 2014.) Available from www.who.int/medicinedocs/pdf/s2300e/s2300e.pdf
4. World Health Organization. Assessment of medicines regulatory systems in sub-Saharan African countries: an overview of findings from 26 assessment reports. WHO. (Updated 2010. Accessed 11 February 2014.) Available from http://apps.who.int/medicinedocs/en/d/Js17577en
5. World Health Organization, World Intellectual Property Organization and World Trade Organization. Promoting access to medical technologies and innovation. Intersections between public health, intellectual property and trade. WHO, WIPO, WTO. (Updated 2012. Accessed 17 February 2014.) Available from http://www.who.int/phi/PAMTI-WHO-WIPO-WTO.pdf?ua=1
6. ICH. ICH guidelines. (Accessed 11 February 2014.) Available from http://www.ich.org/products/guidelines.html
7. World Health Organization. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for National Medicines Regulatory Authorities (NMRAs). 2nd edition. (Updated 2011. Accessed 23 June 2014.) Available from http://www.who.int/medicines/areas/quality-safety/regulation-legislation/blue-book/en
8. World Health Organization. Medicines: guidelines. (Accessed 11 February 2014.) Available from www.who.int/medicines/areas/quality-safety/quality-assurance/guidelines/en/index.html
9. World Health Organization. The International Pharmacopoeia (Ph. Int.). (Updated 2013. Accessed 11 February 2014.) Available from http://www.who.int/medicines/publications/pharmacopoeia/en
10. 't Hoen EFM, Hogerzeil HV, Quick JD, Sillo HB. A quiet revolution in global public health: the World Health Organization's Prequalification of Medicines Programme. J Public Health Policy 2014;35:137-161.
11. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic 2013. (Updated 2013. Accessed 23 June 2014.) Available from http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/unaids-global-report-2013-en.pdf
12. Prequalification Programme WHO. Annual report 2012. (Accessed 13 May 2014.) Available from http://apps.who. int/prequal/info-general/documents/WHO-PQP-Annual-report-2012web.pdf
13. Waning B, Diedrichsen E, Moon S. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. J Int AIDS Soc 2010;13:35.
14. Prequalification Programme. A United Nations Programme managed by WHO. (Updated 11 February 2014. Accessed 11 February 2014.) Available from http://apps.who.int/prequal
15. WHO Prequalification of Medicines Programme. Investing in WHO prequalification of finished pharmaceutical products. Information for manufacturers. (Updated 2013. Accessed 11 February 2014.) Available from http://apps.who.int/prequal/info-press/documents/WHO-Prequalification-WHY.pdf
16. WHO Prequalification of Medicines Programme. Expert review panel. A rapid quality risk assessment mechanism for assessing needed pharmaceutical products that have not completed a stringent assessment. Briefing paper. (Updated 27 April 2012. Accessed 13 May 2014.) Available from http://apps.who.int/prequal/info-press/documents/ERP-article.pdf
17. WHO Prequalification of Medicines Programme. Expert review panel procedure: additional support to procurement agencies under exceptional circumstances. Prequalification update. (Updated 3 September 2013. Accessed 13 May 2014.) Available from http://apps.who. int/prequal/info-general/documents/ERP/Expanded-ERP-process-Sep2013.pdf
18. Médecins sans Frontières. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries. 6th Edition. (Updated 2004. Accessed 11 February 2014.) Available from http://utw.msfaccess.org/downloads/documents
19. World Trade Organization. The results of the Uruguay round of multilateral trade negotiations. Annex 1C: trade-related aspects of Intellectual Property Rights (TRIPS). (Updated 2007. Accessed 11 February 2014.) Available from http://www.wto.org/english/docs-e/legal-e/legal-e.htm
20. WHO/UNAIDS. Treating 3 million by 2005. Making it happen. The WHO Strategy. (Updated 2003. Accessed 23 June 2014.) Available from http://www.who.int/3by5/publications/documents/isbn9241591129/en
21. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004;364:29-34.
22. The important world of drug prequalification. Lancet 2004;364:1830.
23. African Union. Pharmaceutical Manufacturing Plan for Africa (PMPA). Business plan. (Updated 2012. Accessed 11 February 2014.) Available from http://apps.who.int/medicinedocs/en/d/Js20186en
24. World Health Organization. Effective medicines regulation: ensuring safety, efficacy and quality. WHO Policy Perspective on Medicines No. 7, 2013. (Updated November 2003. Accessed 11 February 2014.) Available from http://apps.who.int/medicinedocs/pdf/s4921e/s4921e.pdf